The FDA this week granted the fourth Orphan Drug Designation for a novel gene therapy product candidate (OCU400, Ocugen Inc.) in the treatment of PDE6B gene mutation-associated retinal diseases.
At this year’s ASCRS meeting in Boston, Massachusetts, Leonard Borrmann, CEO at Centricity Vision, about the company’s new product ZEPTOLink, including first-in-human data.
Need to eliminate errors results in optimization of training of novice surgeons.
According to researchers, insights into the ocular microbiome could have implications beyond eye health.
Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss Susac syndrome, and how leakage on fluorescein…
The LYNX-2 Phase 3 study is evaluating phentolamine ophthalmic solution 0.75% for the treatment of decreased visual acuity under low light conditions following keratorefractive surgery
According to the company, the grant funding from the Choroideremia Research Foundation is in support of validating functional vision assessments for patients with profound blindness.
The switch may produce an additional 25% IOP reduction in mild to moderate forms of disease
Hema Ramkumar, an ophthalmologist and founder of Oculogenex, sat down with David Hutton of Ophthalmology Times to discuss their connection with NASA and their experiment…
Authors explained that Nfe2l gene family members -1, -2, and -3 mediate the cellular response to oxidative stress, including in the CNS
Scientists at the National Institutes of Health use artificial intelligence called ‘P-GAN’ to improve next-generation imaging of cells in the back of the eye.
